GLP-1 nanomedicine alleviates gut inflammation
Open accessAbstract
The gut hormone, glucagon like peptide-1 (GLP-1) exerts anti-inflammatory effects. However, its clinical use is limited by its short half-life. Previously, we have shown that GLP-1 as a nanomedicine (GLP-1 in sterically stabilized phospholipid micelles, GLP-1-SSM) has increased in vivo stability. The current study was aimed at testing the efficacy of this GLP-1 nanomedicine in alleviating colonic inflammation and associated diarrhea in dextran sodium sulfate (DSS) induced mouse colitis model. Our results show that GLP-1-SSM treatment markedly alleviated the colitis phenotype by reducing the expression of pro-inflammatory cytokine IL-1β, increasing goblet cells and preserving intestinal epithelial architecture in colitis model. Further, GLP-1-SSM alleviated diarrhea (as assessed by luminal fluid) by increasing protein expression of intestinal chloride transporter DRA (down regulated in adenoma). Our results indicate that GLP-1 nanomedicine may act as a novel therapeutic tool in alleviating gut inflammation and associated diarrhea in inflammatory bowel disease (IBD).
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
There is evidence that GLP-1RA can reduce intestinal inflammation in IBD by regulating immune cell signaling and having anti-inflammatory properties.
“There is evidence that GLP-1RA can reduce intestinal inflammation in IBD by regulating immune cell signaling and having anti-inflammatory properties. 110”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [110]
The Abstract reports that GLP-1-SSM reduced intestinal inflammation in mice with DSS-induced colitis, and the Discussion describes GLP-1’s anti-inflammatory effects on immune-cell activity. But the study did not establish immune-cell signaling as the mechanism of the intestinal effect; it says GLP-1 receptor activation may mediate the observed effects. The evidence is for a specific GLP-1 formulation in mice, not GLP-1 receptor agonists as a class in people with IBD. (LLM, conf=0.86)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371 · see citing works
Pharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500 · see citing works
The SLC26 gene family of multifunctional anion exchangers
Mount, D. B., & Romero, M. F. (2004) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-003-1090-3 · Cited by 533 · see citing works
GLP-1 receptor agonists: a review of head-to-head clinical studies
Trujillo, J. M., Nuffer, W., & Ellis, S. L. (2015) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018814559725 · Cited by 282 · see citing works
Asano, K., Matsushita, T., Umeno, J., Hosono, N., Takahashi, A., Kawaguchi, T., Matsumoto, T., Matsui, T., Kakuta, Y., Kinouchi, Y., et al. (2009) · Nature Genetics · doi:10.1038/ng.482 · Cited by 276 · see citing works
Suppression of experimental colitis by intestinal mononuclear phagocytes
Qualls, J. E., Kaplan, A. M., van Rooijen, N., & Cohen, D. A. (2006) · Journal of Leukocyte Biology · doi:10.1189/jlb.1205734 · Cited by 237 · see citing works
Schweinfest, C. W., Spyropoulos, D. D., Henderson, K. W., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m607527200 · Cited by 224 · see citing works
Vong, L. B., Tomita, T., Yoshitomi, T., Matsui, H., & Nagasaki, Y. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.06.043 · Cited by 196 · see citing works
Hogan, A. E., Tobin, A. M., Ahern, T., Corrigan, M. A., Gaoatswe, G., Jackson, R., O’Reilly, V., Lynch, L., Doherty, D. G., Moynagh, P. N., et al. (2011) · Diabetologia · doi:10.1007/s00125-011-2232-3 · Cited by 191 · see citing works
Koehler, J. A., Baggio, L. L., Lamont, B. J., Ali, S., & Drucker, D. J. (2009) · Diabetes · doi:10.2337/db09-0626 · Cited by 160 · see citing works
Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue
Russell-Jones, D. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.11.018 · Cited by 137 · see citing works
Yang, H., Jiang, W. G., Furth, E. E., et al. (1998) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1998.275.6.g1445 · Cited by 121 · see citing works
Priyamvada, S., Gomes, R., Gill, R. K., Saksena, S., Alrefai, W. A., & Dudeja, P. K. (2015) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000504 · Cited by 117 · see citing works
Self-citationDai, Y., Dai, D., Wang, X., Ding, Z., & Mehta, J. L. (2014) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-014-6539-4 · Cited by 116 · see citing works
Corridoni, D., Arseneau, K. O., & Cominelli, F. (2014) · Immunology Letters · doi:10.1016/j.imlet.2014.04.004 · Cited by 111 · see citing works
Kwon, H.-S., Oh, S.-M., & Kim, J.-K. (2007) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2007.03539.x · Cited by 107 · see citing works
Nanotechnology in the treatment of inflammatory bowel diseases
Viscido, A., Capannolo, A., Latella, G., Caprilli, R., & Frieri, G. (2014) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2014.02.024 · Cited by 94 · see citing works
Xiao, F., Yu, Q., Li, J., Johansson, M., Singh, A. K., Xia, W., Riederer, B., Engelhardt, R., Montrose, M. H., Soleimani, M., et al. (2013) · Acta Physiologica · doi:10.1111/apha.12220 · Cited by 88 · see citing works
Marrero, J. A., Matkowskyj, K. A., Yung, K., Hecht, G. A., & Benya, R. V. (2000) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.2000.278.5.g797 · Cited by 85 · see citing works
Jungraithmayr, W., Meester, I. D., Matheeussen, V., et al. (2011) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezr180 · Cited by 69 · see citing works
A Novel Peptide Nanomedicine Against Acute Lung Injury: GLP-1 in Phospholipid Micelles
Lim, S. B., Rubinstein, I., Sadikot, R. T., Artwohl, J. E., & Önyüksel, H. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0322-4 · Cited by 67 · see citing works
Upregulation of CFTR expression but not SLC26A3 and SLC9A3 in ulcerative colitis
Lohi, H., Mäkelä, S., Pulkkinen, K., et al. (2002) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00356.2001 · Cited by 66 · see citing works
Pugazhenthi, U., Velmurugan, K., Tran, A., Mahaffey, G., & Pugazhenthi, S. (2010) · Diabetologia · doi:10.1007/s00125-010-1849-y · Cited by 61 · see citing works
Exendin-4, but not dipeptidyl peptidase IV inhibition, increases small intestinal mass in GK rats
Simonsen, L., Pilgaard, S., Ørskov, C., ROSENKILDE, M. M., Hartmann, B., Holst, J. J., & Deacon, C. F. (2007) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00453.2006 · Cited by 55 · see citing works
Novel, Biocompatible, and Disease Modifying VIP Nanomedicine for Rheumatoid Arthritis
Sethi, V., Rubinstein, I., Kuzmis, A., et al. (2012) · Molecular Pharmaceutics · doi:10.1021/mp300539f · Cited by 49 · see citing works
Potential prospects of nanomedicine for targeted therapeutics in inflammatory bowel diseases
Pichai, M. V. A. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i23.2895 · Cited by 46 · see citing works
Chen, S., Bastarrachea, R. A., Roberts, B. J., Voruganti, V. S., Frost, P. A., Nava‐González, E. J., Arriaga-Cázares, H. E., Chen, J., Huang, P., DeFronzo, R. A., et al. (2014) · Cell Cycle · doi:10.4161/cc.27997 · Cited by 36 · see citing works
Singh, V., Kumar, A., Raheja, G., et al. (2014) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00104.2014 · Cited by 33 · see citing works
Self-citationChouliaras, G. L., Panayotou, I., Margoni, D., et al. (2013) · Pediatric Research · doi:10.1038/pr.2013.114 · Cited by 26 · see citing works
Potential prospects of nanomedicine for targeted therapeutics in inflammatory bowel diseases
Madharasi, Va, Pichai, et al. (2012) · Acta Scientiarum Naturalium Universitatis Sunyatseni · Cited by 25 · see citing works
JNK3 Is Required for the Cytoprotective Effect of Exendin 4
Ezanno, H., Pawlowski, V., Abdelli, S., Boutry, R., Gmyr, V., Kerr-Conte, J. A., Bonny, C., Pattou, F. N., & Abderrahmani, A. (2014) · Journal of Diabetes Research · doi:10.1155/2014/814854 · Cited by 23 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications
Alharbi, S. H. (2024) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188231222367 · Cited by 358 · see citing works
Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent
Mehdi, S. F., Pusapati, S., Anwar, M. S., Lohana, D., Kumar, P., Nandula, S. A., Nawaz, F. K., Tracey, K., Yang, H., LeRoith, D., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1148209 · Cited by 317 · see citing works
Zheng, M., Han, R., Yuan, Y., Xing, Y., Zhang, W., Sun, Z., Liu, Y., Li, J., & Mao, T. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1089600 · Cited by 241 · see citing works
GLP-1 and GLP-2 Orchestrate Intestine Integrity, Gut Microbiota, and Immune System Crosstalk
Abdalqadir, N., & Adeli, K. (2022) · Microorganisms · doi:10.3390/microorganisms10102061 · Cited by 119 · see citing works
GLP-1 based therapies and disease course of inflammatory bowel disease
Villumsen, M., Schelde, A. B., Jimenez-Solem, E., Jess, T., & Allin, K. H. (2021) · eClinicalMedicine · doi:10.1016/j.eclinm.2021.100979 · Cited by 97 · see citing works
Hunt, J. E., Holst, J. J., Jeppesen, P. B., & Kissow, H. (2021) · Biomedicines · doi:10.3390/biomedicines9040383 · Cited by 65 · see citing works
Sun, H., Shu, J., Tang, J., Li, Y., Qiu, J., Ding, Z., Xuan, B., Chen, M., Gan, C., Lin, J., et al. (2024) · Immunology · doi:10.1111/imm.13784 · Cited by 54 · see citing works
Pang, J., Feng, J. N., Ling, W., & Jin, T. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.06.003 · Cited by 52 · see citing works
- Authors
- Anbazhagan, A. N., Thaqi, M., Priyamvada, S., Jayawardena, D., Kumar, A., Gujral, T., Chatterjee, I., Mugarza, E., Saksena, S., Onyuksel, H., & Dudeja, P. K.
- Affiliations
- University of Illinois Chicago (US)
- Corresponding author
- Dudeja, Pradeep K.
- ORCID
- Venue
- Nanomedicine: Nanotechnology, Biology and Medicine
- Publisher
- Elsevier BV
- Published
- 2017-02
- Volume
- 13
- Issue
- 2
- Pages
- 659-665
- ISSN
- 1549-9634 (ISSN-L)
- PMC
- PMC5501083
- OpenAlex
- W2512047843
- Cited by
- 80
- References
- 31
- Citations by year
- 2026: 9 · 2025: 10 · 2024: 12 · 2023: 6 · 2022: 12 · 2021: 12 · 2020: 4 · 2019: 7 · 2018: 4 · 2017: 3
- FWCI
- 3.77
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nanomedicine Nanotechnology Biology and Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- U.S. Department of Veterans Affairs (I01 BX002867, I01BX002011)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK054016, R21DK096254, R01DK081858, R56DK092441, R01DK092441)
- National Center for Research Resources (C06RR015482)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Inflammatory Bowel Disease
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- glucagon-like peptide-1, intestinal inflammation, colitis, DSS-induced colitis, inflammatory bowel disease, diarrhea, IL-1β, goblet cells, DRA, anti-inflammatory therapy
- MeSH terms
- Animals, Colitis, Diarrhea, Disease Models, Animal, Inflammation, Dextran Sulfate, Nanomedicine, Mice, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
